On Monday, Citi reiterated a Impartial score on 23andMe Holding Co (NASDAQ:ME) inventory with a value goal of $0.42. The agency’s commentary adopted the presentation of extra trial information by 23andMe on the European Society of Medical Oncology (ESMO) Congress.
The info included outcomes from the Section 1/2a trial of 23ME-00610, an anti-CD200R1 antibody, and non-clinical outcomes for 23ME-01473, an anti-ULBP6 antibody.
Within the trial for 23ME-00610, one partial response was noticed within the clear-cell renal-cell carcinoma (ccRCC) cohort, which consisted of ten sufferers. The response indicated a 38% discount in measured tumor burden.
Moreover, the corporate introduced information from 13 sufferers with regionally superior or metastatic excessive tumor burden (TMB-Excessive; n=11) and/or excessive tumor microsatellite instability (MSI; n=5). The outcomes confirmed acceptable tolerability and full peripheral goal engagement, however restricted anti-tumor exercise when used as a monotherapy.
The analyst from Citi famous that whereas the info are intriguing, they’re nonetheless preliminary and contain a small pattern measurement. The main focus for traders, in response to the agency, is more likely to stay on potential updates concerning Anne Wojcicki’s acquisition bid for 23andMe. Traders are additionally looking for any different gives following Wojcicki’s current assertion expressing openness to contemplating third-party takeover proposals.
The continuing curiosity in 23andMe’s company developments, together with the acquisition talks, is a major level of consideration for shareholders and potential traders. Because the scenario evolves, updates on these company actions are extremely anticipated within the funding group.
In different current information, 23andMe Holding Co. reported a 34% lower in Q1 2025 income, falling to $40 million, primarily as a result of finish of a partnership with GSK. Nevertheless, the corporate’s internet loss for the quarter improved, standing at $69 million in comparison with the earlier 12 months’s $105 million.
A subsidiary of 23andMe, Lemonaid Well being, has launched a brand new weight reduction program that features entry to GLP-1 drugs similar to Ozempic®, Wegovy®, and compounded semaglutide, out there via a month-to-month subscription mannequin.
Moreover, 23andMe shareholders authorised a reverse inventory break up, consolidating excellent Class A and Class B frequent inventory at a ratio to be decided by the board. Anne Wojcicki and Peter Taylor have been re-elected to the corporate’s Board of Administrators, as reported in a current 8-Ok submitting.
The corporate can be actively creating AI fashions and has launched a large-scale genetic examine, demonstrating its dedication to advancing its therapeutics and analysis capabilities. These are current developments that traders ought to concentrate on.
This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.